Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)
Sponsor: Abbott
Terminated
Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.
A PHASE4 clinical study on Atherosclerosis, this trial is terminated or withdrawn. The trial is conducted by Abbott and has accumulated 10 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE4
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Walter Reed Army Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .